Adaptive Biotechnologies Corp
ADPTQ4 2023(ADPT Q3 FY2023)Estimated8% AI
AI Revenue %
8%
AI Fair Value
$77.6M
AI Revenue (Q)
$3.0M
Total Revenue (Q)
$37.9M
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Revenue of $37.9M, a decline from Q2 2023's $48.9M, consistent with large Q2 2023 Genentech milestone not repeating. Genentech was not a >10% customer in Q3 2023 standalone. IM revenue likely returned to ~$6-8M run rate. Applying 50% AI attribution: ~$3-4M / $37.9M = ~8-10%. Using 8% conservatively given weaker quarter and no milestone.
Analyzed by claude-opus-4-6
Quoted Figures
Revenue $37,919K for three months ended September 30, 2023
10-Q filed 2023-11-07, Income Statement
Nine months ended September 30, 2023 revenue $124,492K
10-Q filed 2023-11-07, Income Statement
AI Products Identified (Ring 1)
Immune Medicine TCR-Antigen MapAdaptive Immunosequencing
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
clonoSEQ diagnostic testMRD Pharma testing services
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix